315 related articles for article (PubMed ID: 22432738)
1. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
3. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
4. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
[TBL] [Abstract][Full Text] [Related]
7. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
8. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Michaelis M; Fichtner I; Behrens D; Haider W; Rothweiler F; Mack A; Cinatl J; Doerr HW; Cinatl J
Int J Oncol; 2006 Feb; 28(2):439-46. PubMed ID: 16391799
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.
Rückrich T; Kraus M; Gogel J; Beck A; Ovaa H; Verdoes M; Overkleeft HS; Kalbacher H; Driessen C
Leukemia; 2009 Jun; 23(6):1098-105. PubMed ID: 19225532
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
14. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
[TBL] [Abstract][Full Text] [Related]
15. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Seavey MM; Lu LD; Stump KL; Wallace NH; Ruggeri BA
Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Niewerth D; Jansen G; Assaraf YG; Zweegman S; Kaspers GJ; Cloos J
Drug Resist Updat; 2015 Jan; 18():18-35. PubMed ID: 25670156
[TBL] [Abstract][Full Text] [Related]
17. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
19. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Altun M; Galardy PJ; Shringarpure R; Hideshima T; LeBlanc R; Anderson KC; Ploegh HL; Kessler BM
Cancer Res; 2005 Sep; 65(17):7896-901. PubMed ID: 16140960
[TBL] [Abstract][Full Text] [Related]
20. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
O'Connor OA; Smith EA; Toner LE; Teruya-Feldstein J; Frankel S; Rolfe M; Wei X; Liu S; Marcucci G; Chan KK; Chanan-Khan A
Clin Cancer Res; 2006 May; 12(9):2902-11. PubMed ID: 16675587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
